1 / 17

ROLE OF TUMOUR MARKERS IN CANCER MANAGEMENT

ROLE OF TUMOUR MARKERS IN CANCER MANAGEMENT. PROFESSOR V. K. GOLAKAI BSc, MD, ChM, FWACS, FICS, DSc(Med) PRINCESS MARINA HOSPITAL. DEFINITION. Glyco- / lipoproteins produced by: malignant cells normal cells in response to tumour inflammatory cells and tissues

Rita
Download Presentation

ROLE OF TUMOUR MARKERS IN CANCER MANAGEMENT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ROLE OF TUMOUR MARKERS IN CANCER MANAGEMENT PROFESSOR V. K. GOLAKAI BSc, MD, ChM, FWACS, FICS, DSc(Med) PRINCESS MARINA HOSPITAL

  2. DEFINITION Glyco- / lipoproteins produced by: • malignant cells • normal cells in response to tumour • inflammatory cells and tissues • found in serum, urine, body fluids • react with man-made antibodies or • combine with man-made antigens • cyto- / histo-compatibility reaction to form • cyto- / histocompatibility complexes

  3. TYPES OF TUMOUR MARKERS • Tumour-Associated Proteins (TAP) • Cell membrane receptors • Hormones • Immunoglobulins / Cellular antigens • Polyamines • Protein clusters and fragments • Chromosomal material • Genes (single, clusters) • Genetic material (DNA, RNA, mRNA) • Cell modulators (transducers / suppressors)

  4. Specific Classes of TM’s • Enzymes (PSA, NSE, VMA, HVA) • Cell membrane receptors (ER, PR) • Tumour antigens (CEA, AFP) • Antibodies (IgA, IgG, IgM, IgD) • Antigens (p53, ki-62) • CA-specific proteins(CA 19-9, CA 124) • Gene mutation products (BR CA 1, 2)

  5. Specific Classes of TM’s (2) • Tissue-specific proteins (PSA, hCGH) • Special hormones (b-hCGH, h-CGH) • Catecholamines (VMA, HVA, ACTH) • Polyamines • Cytoplasmic / Nucleic material (DNA) • Products of cell turn-over (TNF) • Cellular modulators (ki-62, c-erb-2)

  6. WHO CRITERIA (1) [968] • Important role in evaluation • Role must be well understood • Role must be recognized • Can be tested early • Detects treatment response

  7. WHO CRITERIA (2) [1968] • Support for test available • Support / treatment beneficial • Benefits greater than side-effects • Screening must be cost-effective • Detect / diagnose malignant disease

  8. Types of test kits • ELISA Test Kits • Immuno-histochemical kits (ICH) • Polymerase chain reaction (PCR) • Cluster Kits ( All-in-One Kit) • Detects profiles • Patterns • Prototypes • Constellations

  9. METHODS OF ANALYSIS • Expression of single proteins • Expression of multiple proteins • Chip analysis – “All-in-One” • Expression of protein profiles (Proteonomics) • Gene methylation at DNA level • Genes / mutations (Genomics) • G-scan (genome ID scan)

  10. hCGH (specific) beta-hCGH dto CEA (NS) AFP (NS) Bence-Jones (MM) Beta-2-M (S) BTA (Bladder) (S) CgA (Chromogranin-A) CA-15-3 (NS) CA-19-9 (NS) CA-72-4 (NS) CA-27.29 (NS) CA-125 (NS) ER / PR (Breast) HER-2 neu (c-erbB-2) BR CA-1 / BR CA-2 COMMON TUMOUR MARKERS IN CLINICAL PRACTICE

  11. LASA-P (S) NM-22 (S) PSA (Prostate-S) PSMA (Prostate-S) S-100 (Melanoma) TA-90 (NS) TgA, IgA, D, G, M TPA (NS) Alk. p’tase (mets) Alpha Amylase SIADH, ACTH, ADH GT-II (NS) VMA, HVA (S) Polyamines (NS) Genes (k-ras, ki-62) Chromosome (p53) COMMON TUMOUR MARKERS IN CLINICAL PRACTICE (2)

  12. Clinical uses of TM’s • Screening populations at risk • Early detection of tumour • Diagnosing and aiding diagnosis • Predicting response to treatment • Monitoring patients with cancer

  13. Clinical uses of TM’s (2) • Assessing prognosis in cancer • Differentiating malignant v benign • Predicting / detecting recurrence • Evaluating extent of disease • Targeting localisation & therapy

  14. Short-comings of TM’s • TM’s are not specific enough • TM’s are not sensitive enough • Not produced by cancer cells alone • TM’s are not ideal for evaluating CA • Poor detectors / predictors early CA • Not good enough prognosticators • TM testing hindered by “Hook effect”

  15. NEW FRONTIERS • Genomics – Gene structure • Proteonomics – Protn structure • Pharmacogenomics – Gene-based drugs structuring and delivery • G-scan – Human genome mapping • New treatment modalities • Individualised treatment modalities • Early detection of malignant change • Greater sensitivity and specificity • Better monitoring and follow-up care

  16. PHARMACOLOY BRAVE NEW SCIENCE Protein based drugs Stem cell biology GENETIC REVOLUTION TM DNA-Genome PROTEONOMICS CYTOGENES Gene chips G scan Antibiotics, antimicrobials PHARMACO GENETIC TESTS PERFECT HEALTH REGENERATIVE MEDICINE DISEASE DEATH PROCREATION IMORTALITY/LOGNGEVITY BIRTH REGENERATIVE MEDICNE GERM-LINE GENOMICS HUMAN TRAIT ALTERATIONS

  17. REGENERATIVE MEDICINE: BRAVE NEW WORLD • Instead of cutting flesh with steel and poisoning the body with chemicals or burning it with radiation; • Physicians would gently treat the body with nothing but proteins and cells, seeking to mend like with like. • Instead of depending only on his knowledge and limited and erratic skills snf methods; • Physicians would seek to tap information in the genome and to exploit the fact that the body’s cells are designed to be a self- modulating self-assembling system when given proper signals. • Instead of sending a patient home merely patched up enough to live with simmering uncured disease or decaying cells; • The physician would not rest until the damaged tissues were replaced with ones as good as new, if not better.

More Related